Re-Pharm, an early-stage drug discovery and development company that uses computational chemistry for re-profiling, is pleased to announce that Dr Robert Scoffin, CEO, will be presenting at the Annual Congress of International Drug Discovery Science and Technology (IDDST) in Nanjing, China on 16-19 November 2016.

Dr Scoffin will also be available for one-to-one partnering meetings throughout the show. Dr Scoffin’s talk, ‘Finding new uses for an old drug through computational chemistry – re-profiling of RP0217 as a novel topical anti-inflammatory treatment’, on Saturday 19^th November, will describe Re-Pharm’s smart re-profiling platform, which has been used to discover novel anti-inflammatory activity for a 60 year old drug.

Re-Pharm is actively looking for partners to progress the anti-inflammatory compound RP0217 through early clinical development and clinical trials. Re-Pharm holds patents on the use of RP0217 for the treatment or prevention of respiratory and gastrointestinal inflammatory disorders and for its use with and without co-formulated or co-administered steroids in topical ophthalmic indications, specifically conjunctivitis and uveitis, and prophylactic use in surgical applications such as LASIK.

“Re-Pharm uses in silico approaches to rapidly explore re-profiling and re-purposing opportunities for marketed compounds,” explains Scoffin. “Compounds with potential are progressed rapidly through our optimization and validation process. Re-purposed compounds such as RP0217 have significant bodies of safety data available, which typically result in shortened routes to regulatory approval.”

more about re-pharm